Soligenix, Inc. announced on October 7, 2024, that lead investigators presented expanded findings from supportive trials of HyBryte™ (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL) at the European Organisation for Research and Treatment of Cancer (EORTC) conference. The presentations occurred on October 9-11, 2024, in Lausanne, Switzerland.
The data highlighted the utility of longer treatment times, the lack of significant systemic exposure to hypericin after topical application, and its relative efficacy and tolerability compared to Valchlor®. These findings further support HyBryte's potential as a differentiated therapy for CTCL.
The company also reiterated that the second, confirmatory Phase 3 study, known as FLASH2, is expected to be initiated before the end of 2024. This study aims to further validate HyBryte's efficacy and safety, moving closer to potential regulatory approvals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.